From Secfilings.com

Prurisol has demonstrated strong potential in laboratory studies where it outperformed methotrexate, a standard of care today for psoriasis. "Mice treated with Prurisol showed no reoccurrence of psoriatic lesions during the experiment, whereas animals treated with MTX showed a median reoccurrence of lesions by the 57th day,” according to documents submitted to the FDA by Cellceutix.

A good benchmark for the value of Prurisol can be gauged by the recent activity of Steifel Labs, a GlaxoSmithKline (NYSE: GSK) company. Steifel said it will be spending approximately $350 million to acquire rights to skin treatment drugs still in development from Welichem Biotech and Basilea Pharmaceutica. It is noteworthy that Steifel’s acquisition is for topical treatments.

Prurisol is being synthesized into an oral medication which should give it a value of potentially many multiples of the Steifel compound if a therapeutic benefit can be observed in humans.